Printer Friendly

BIOSOURCE INTERNATIONAL ANNOUNCES THREE NEW PRODUCTS; RELEASES ULTRA- SENSITIVE VERSIONS OF TWO ELISA ASSAYS AND NEW STEM CELL FACTOR KIT

 CAMARILLO, Calif., Nov. 15 /PRNewswire/ -- BioSource International Inc. (NASDAQ: BIOI) today announced the immediate availability of three new test kits for medical research applications. Two of the products are ultra-sensitive versions of the company's ELISA assays for measuring human Interleukin-10 (IL-10) and human interleukin-6 (IL-6). The third is a new ELISA assay for measuring Stem Cell Factor (SCF).
 The new "CytoScreen-US (TM)" (Ultra Sensitive) assays are approximately one hundred times more sensitive than any standard assays, making it possible to detect IL-10 and IL-6 at femtogram/milliliter levels in human serum, plasma or culture supernatants. Standard assays measure picogram/milliliter levels, which often is not sensitive enough to detect the low levels of these immune proteins found in body fluids. The Ultra-Sensitive assays may broaden the market for these test kits, since the substances they detect show promise as potential diagnostics for a number of immune disorders and several forms of cancer.
 The immunomodulator IL-10 is a cytokine protein that is produced by cells isolated from patients with AIDS and Burkitt's Lymphoma, and may eventually prove to be a diagnostic for one or more of these conditions. The IL-6 molecule is being evaluated by researchers as a potential diagnostic for autoimmune diseases, such as arthritis and Castleman's disease, as well as several forms of cancer.
 "Our standard assays for both IL-10 and IL-6 already are high demand products," said Jim Chamberlain, president and CEO of BioSource. "We expect that the Ultra-Sensitive versions will broaden the potential use of the kits form pure research applications into the clinical research area.
 "Because these kits represent a new market opportunity, it is difficult to estimate their revenue potential. We do expect that the Ultra-Sensitive IL-10 kit will surpass the one-half million dollar annual run rate of our current IL-10 line, without reducing revenue from that product," said Chamberlain.
 The third new ELISA assay, "Cytoscreen (TM) SCF/C-Kit Ligand," measures the presence of Stem Cell Factor, an important growth factor in the development of red blood cells and myeloid cells. This molecule is secreted by bone marrow and liver cells, among others, and acts upon the earliest progentior cells of the immune system. SCF has potential for improving transplantation and chemotherapy, and has been approved for clinical trials as a treatment for anemia.
 All three of the ELISA assays are shipped by BioSource with two test plate kits in each package and all materials needed to test up to 192 samples. For more information, or to order kits, researchers can call 800-242-0607.
 BioSource International Inc. is a Camarillo-based supplier of immunological reagents and test kits used in biomedical research. The company offers more than 600 products, including recombinant proteins, monoclonal antibodies and ELISA assay kits to a variety of antigens. Incorporated in 1989, the company was listed on Nasdaq in May 1993, after completing the acquisition of Tago, Inc. Combined FY 1992 revenues of the merged company were $4 million. Revenues in the first nine months of 1993 (Jan. 1-Sept. 30) were $4.06 million and the company reported net income of $419,021. CytoScreen and CytoScreen-US are trademarks of BioSource International Inc.
 -0- 11/13/93
 /CONTACT: James Chamberlain, or Anna Anderson, treasurer, of BioSource International, 805-987-0086 or Matthew Schmidt of FS Communications, 415-691-1488/
 (BIOI)


CO: BioSource International Inc. ST: California IN: MTC SU: PDT

LG -- NY015 -- 4393 11/15/93 12:00 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 15, 1993
Words:561
Previous Article:DISCUS ANNOUNCES RESULTS FOR THE THIRD QUARTER OF 1993
Next Article:SYSTEMIX REPORTS THIRD QUARTER AND NINE MONTH RESULTS
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters